603669.SHG Lionco Pharm Grp Co Ltd
- Market cap
- CNY 3.90B
- P/E
- -
- P/B
- 5.67x
- ROE
- 6.5%
- Dividend yield
- 0.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603669.SHG undervalued?
Graham numberThe Graham number of Lionco Pharm Grp Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lionco Pharm Grp Co Ltd fundamental analysis
No fundamental analysis for Lionco Pharm Grp Co Ltd yet.
Lionco Pharm Grp Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China.
Full company profileLionco Pharm Grp Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lionco Pharm Grp Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 479M | 1.01B | 1.67B | 1.64B | 1.00B | 740M | 289M | 197M | 380M | 322M | 480M |
| Gross Profit | 275M | 804M | 1.47B | 1.41B | 836M | 585M | 195M | 87.0M | 173M | 141M | 232M |
| Operating Income | 129M | 182M | 209M | 223M | 181M | 71.1M | -189M | -149M | -129M | -93.3M | 76.0M |
| EBITDA | 205M | 210M | 236M | 272M | 228M | 126M | -140M | -103M | -71.4M | -139M | 65.2M |
| Net Income | 154M | 161M | 183M | 202M | 160M | 65.9M | -196M | -151M | -131M | -193M | 42.4M |
| EPS | 0.22 | 0.22 | 0.26 | 0.28 | 0.21 | 0.09 | -0.27 | -0.21 | -0.18 | -0.27 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.34B | 1.65B | 2.07B | 1.91B | 2.72B | 2.51B | 1.86B | 1.62B | 1.26B | 1.11B | 1.15B |
| Total Liabilities | 175M | 352M | 690M | 600M | 1.24B | 1.06B | 720M | 694M | 486M | 486M | 495M |
| Shareholders' Equity | 1.17B | 1.30B | 1.38B | 1.31B | 1.48B | 1.46B | 1.14B | 931M | 770M | 620M | 652M |
| Cash & Short-term Investments | 220M | 313M | 711M | 867M | 1.75B | 1.57B | 965M | 734M | 285M | 156M | 151M |
| Total Debt | 52.8M | 70.4M | 395M | 250M | 915M | 949M | 620M | 566M | 262M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 182M | 189M | 186M | 236M | 127M | 129M | -66.4M | -37.9M | -111M | -133M | - |
| Capital Expenditure | 88.9M | 86.6M | 174M | 10.9M | 62.0M | 54.8M | 42.8M | 23.1M | 8.85M | 2.68M | 2.94M |
| Free Cash Flow | 93.3M | 102M | 12.2M | 225M | 64.9M | 73.7M | -109M | -61.0M | -120M | -136M | -35.9M |
| Ratios | |||||||||||
| ROE | 13.2% | 12.4% | 13.3% | 15.3% | 10.8% | 4.5% | -17.3% | -16.3% | -17.0% | -31.2% | 6.5% |
| ROA | 11.5% | 9.7% | 8.8% | 10.5% | 5.9% | 2.6% | -10.6% | -9.3% | -10.4% | -17.5% | 3.7% |
| Net Profit Margin | 32.2% | 16.0% | 10.9% | 12.3% | 16.0% | 8.9% | -67.7% | -77.0% | -34.4% | -59.9% | 8.8% |
| Debt to Equity | 0.05x | 0.05x | 0.29x | 0.19x | 0.62x | 0.65x | 0.55x | 0.61x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lionco Pharm Grp Co Ltd dividends
- Dividend yield
- 0.17%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 5, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 6.59M | 0.01 | - |
| 2024 | CNY 5.73M | 0.01 | - |
| 2023 | CNY 8.08M | 0.01 | - |
| 2022 | CNY 71.8M | 0.10 | - |
| 2021 | CNY 159M | 0.22 | 241.6% |
| 2020 | CNY 102M | 0.13 | 63.7% |
| 2019 | CNY 266M | 0.37 | 131.8% |
| 2018 | CNY 106M | 0.15 | 58.0% |
| 2017 | CNY 31.2M | 0.04 | 19.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 26, 2020.
Who owns Lionco Pharm Grp Co Ltd
- Insiders 61.17%
- Institutions 0.70%
- Public & others 38.14%
- Shares outstanding 712M
- Free float 279M
Lionco Pharm Grp Co Ltd company profile
- Company name
- Lionco Pharm Grp Co Ltd
- Ticker
- 603669.SHG
- ISIN
- CNE1000022R8
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 21, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 284
- Fiscal year end
- December
- Address
- No. 20, National Highway 349, Shannan, China, 856100
- Phone
- 86 89 3783 0666
- Website
- lingkang.com.cn
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China.
Lionco Pharm Grp Co Ltd management
4- Mr. Xiao Gang TaoGM & Director · born 1976
- Mr. Jun Ke ZhangAccounting Supervisor & Financial Director · born 1986
- Mr. Li Ming LiuDeputy GM & Director · born 1975
- Mr. Guo Ping SuiVP & Board Secretary · born 1973